Platform

ALiCE a novel Cell engaging bi-specific antibody

Bispecific antibodies combine two therapeutic antibodies in one, simultaneously utilizing the effect of both to benefit patients. However, currently available technologies have certain limitations in toxicity & immunogenicity. Our new platform technology ALiCE has potential to address these unmet needs by utilizing innate assembly mechanism of the Cell Lines.

ALiCE : Antibody Like Cell EngagerNovel bispecific Antibody Platform Technology
A proprietary bi-specific antibody platform with unique two by one structure to minimize the toxicity.
ALiCE preserves the F(ab’)2 structure of the parental antibody to maintain high binding affinity to the cancer antigen and substitutes the Fc region with a monovalent Fv to induce immune response.

ALiCE Points of Differentiation

Safety(Minimizing Off-target Cytotoxicity)
Modulating avidity of respective binding arms. ALiCE binds to tumor cells with two binding arms and recruit effector cells with only one binding arm. The two-by-one structure resulting in higher avidity for tumor cells to minimize off-target toxicity.

 

Immunogenicity(Bispecific Antibody Without Mutated Structure)
Unlike other bispecific antibodies with mutated structures or linkers, ALiCE enables to create bispecific antibodies composed of only natural elements.

 

Easy to Make(Utilizing innate assembly mechanism of Cell Lines)
In contrast to mutation-based engineering, ALiCE harnesses a natural assembly mechanism in cell lines, elegantly utilizing the innate affinity of VH-VL to form heterodimerization of the heavy chain.

Publication Download